Gamida Cell

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Gamida Cell sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 6 completed early-phase tilt upper quartile by trial count

Gamida Cell: 8 sponsored US clinical trials, none currently recruiting.

Gamida Cell sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematological Malignancies, with 2 trials.

Upper-quartile sponsor footprint

Gamida Cell sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

TERMINATED Phase 1

Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL

NCT05296525
COMPLETED Phase 3

Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies

NCT04260698
COMPLETED Phase 3

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

NCT02730299
TERMINATED Phase 1

Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies

NCT02504619
COMPLETED

Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients

NCT02039557
COMPLETED Phase 1

Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM

NCT01816230
COMPLETED Phase 1

Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies

NCT01590628
COMPLETED Phase 1

Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies

NCT01221857

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 3 2

Therapeutic Areas

Hematological Malignancies 2
Myelodysplastic Syndrome (MDS) 1
Acute Myeloid Leukemia (AML) 1
Acute Lymphoblastic Leukemia (ALL) 1

How the Gamida Cell early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 6 completed (75%).

Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Hematological Malignancies (2 trials), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Gamida Cell: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Gamida Cell sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Gamida CellAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Gamida Cell sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Gamida Cell sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Gamida Cell page

8 registered trials is a research-attention snapshot, not an endorsement of Gamida Cell or any single study.

  • None of Gamida Cell's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Hematological Malignancies is the condition Gamida Cell studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hematological Malignancies trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Gamida Cell pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.